

# Helena Marzo-Ortega

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/7029123/helena-marzo-ortega-publications-by-year.pdf>

**Version:** 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

135  
papers

7,889  
citations

41  
h-index

88  
g-index

159  
ext. papers

9,781  
ext. citations

4.5  
avg, IF

5.48  
L-index

#	Paper	IF	Citations
135	Poor health and functioning in patients with axial spondyloarthritis during the COVID-19 pandemic and lockdown: REUMAVID study (phase 1).. <i>Therapeutic Advances in Musculoskeletal Disease</i> , <b>2022</b> , 14, 1759720X211066685	3.8	1
134	Exploring the role of rheumatic and musculoskeletal disease patient organisations during the COVID-19 pandemic: results from the REUMAVID study (phase 1).. <i>Clinical and Experimental Rheumatology</i> , <b>2022</b> ,	2.2	
133	Correspondence on 'No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post-hoc analyses of psoriatic arthritis-related 'physician-reported spondylitis'?' by Braun and Landewé <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> ,	2.4	1
132	Ultrasound shows swollen joints are the better proxy for synovitis than tender joints in DMARD-naïve early psoriatic arthritis.. <i>Rheumatology Advances in Practice</i> , <b>2021</b> , 5, rkab086	1.1	0
131	Impact of COVID-19 containment measures on patients with rheumatic and musculoskeletal disease in the UK and Europe: the REUMAVID study (phase 1).. <i>Rheumatology Advances in Practice</i> , <b>2021</b> , 5, rkab098	1.1	1
130	Rapid improvement in spinal pain in patients with axial spondyloarthritis treated with secukinumab: primary results from a randomized controlled phase-IIIb trial. <i>Therapeutic Advances in Musculoskeletal Disease</i> , <b>2021</b> , 13, 1759720X211051471	3.8	0
129	A Pooled Analysis Reporting the Efficacy and Safety of Secukinumab in Male and Female Patients with Ankylosing Spondylitis. <i>Rheumatology and Therapy</i> , <b>2021</b> , 8, 1775-1787	4.4	0
128	Comment on: Is axial psoriatic arthritis distinct from ankylosing spondylitis with and without concomitant psoriasis?. <i>Rheumatology</i> , <b>2021</b> , 60, e24-e25	3.9	1
127	Chest pain mimicking pulmonary embolism may be a common presentation of COVID-19 in ambulant patients without other typical features of infection. <i>Journal of Internal Medicine</i> , <b>2021</b> , 290, 349-358	10.8	2
126	Assessment of impact of the COVID-19 pandemic from the perspective of patients with rheumatic and musculoskeletal diseases in Europe: results from the REUMAVID study (phase 1). <i>RMD Open</i> , <b>2021</b> , 7,	5.9	15
125	Polygenic Risk Scores have high diagnostic capacity in ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> , 80, 1168-1174	2.4	8
124	Immune-Mediated Disease Flares or New-Onset Disease in 27 Subjects Following mRNA/DNA SARS-CoV-2 Vaccination. <i>Vaccines</i> , <b>2021</b> , 9,	5.3	115
123	POS1175 ASSESSMENT OF THE COVID-19 PANDEMIC FROM THE PERSPECTIVE OF PEOPLE WITH RHEUMATIC MUSCULOSKELETAL DISEASES IN EUROPE. RESULTS FROM THE REUMAVID STUDY (PHASE 1). <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> , 80, 868-869	2.4	
122	OP0252 ARTHRITIS AND ENTHESITIS IN THE HIP AND PELVIS REGION IN SPONDYLOARTHRITIS □ VALIDATION OF TWO WHOLE-BODY MRI METHODS. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> , 80, 153.2-154	2.4	1
121	AB0675 COUNTRY COMPARISON ON THE IMPACT OF THE COVID-19 PANDEMIC ON PATIENTS WITH RHEUMATIC DISEASES. RESULTS FROM THE REUMAVID STUDY (PHASE 1). <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> , 80, 1369-1370	2.4	
120	AB0676 FEARS AND HOPES DURING THE COVID-19 PANDEMIC IN PATIENTS WITH RHEUMATIC DISEASES. RESULTS FROM THE REUMAVID STUDY (PHASE 1). <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> , 80, 1370-1371	2.4	
119	OP0149 RELIABILITY AND RESPONSIVENESS OF TWO OMERACT WHOLE-BODY MRI SCORES OF ENTHESEAL AND JOINT INFLAMMATION IN THE KNEE REGION IN SPONDYLOARTHRITIS. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> , 80, 89-90	2.4	

118	AB0677 GENDER DIFFERENCES ON THE IMPACT OF THE COVID-19 PANDEMIC AND LOCKDOWN IN PATIENTS WITH RHEUMATIC DISEASES. RESULTS FROM THE REUMAVID STUDY (PHASE 1). <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> , 80, 1371-1372	2.4	
117	POS1213 IMPACT OF THE COVID-19 PANDEMIC AND LOCKDOWN ON WELLBEING ON PATIENTS WITH RHEUMATIC DISEASES. RESULTS FROM THE REUMAVID STUDY (PHASE 1). <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> , 80, 889.2-890	2.4	
116	British Association of Sexual Health and HIV national guideline on the management of sexually acquired reactive arthritis 2021. <i>International Journal of STD and AIDS</i> , <b>2021</b> , 32, 986-997	1.4	0
115	Correspondence on 'Safety and efficacy of faecal microbiota transplantation for active peripheral psoriatic arthritis: an exploratory randomised placebo-controlled trial'. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> ,	2.4	1
114	Improving patient care through a collaborative effort in the Leeds Combined Psoriatic Service: an effective provision of multi-specialty input. <i>Rheumatology</i> , <b>2021</b> , 60, 467-470	3.9	0
113	Ixekizumab Improves Patient-Reported Outcomes in Non-Radiographic Axial Spondyloarthritis: Results from the Coast-X Trial. <i>Rheumatology and Therapy</i> , <b>2021</b> , 8, 135-150	4.4	3
112	Achievement of Remission Endpoints with Secukinumab Over 3 Years in Active Ankylosing Spondylitis: Pooled Analysis of Two Phase 3 Studies. <i>Rheumatology and Therapy</i> , <b>2021</b> , 8, 273-288	4.4	7
111	Interferon-related gene expression in response to TNF inhibitor treatment in ankylosing spondylitis patients: a pilot study. <i>Rheumatology</i> , <b>2021</b> , 60, 3607-3616	3.9	2
110	Arthritis and enthesitis in the hip and pelvis region in spondyloarthritis - OMERACT validation of two whole-body MRI methods. <i>Seminars in Arthritis and Rheumatism</i> , <b>2021</b> , 51, 940-945	5.3	2
109	Ixekizumab: an IL-17A inhibitor for the treatment of axial Spondylarthritis. <i>Expert Review of Clinical Immunology</i> , <b>2021</b> , 17, 1059-1071	5.1	0
108	Joint and enthesal inflammation in the knee region in spondyloarthritis - reliability and responsiveness of two OMERACT whole-body MRI scores. <i>Seminars in Arthritis and Rheumatism</i> , <b>2021</b> , 51, 933-939	5.3	0
107	Ixekizumab improves sleep and work productivity in patients with non-radiographic axial spondyloarthritis: results from the COAST-X trial at 52 weeks. <i>BMC Rheumatology</i> , <b>2021</b> , 5, 50	2.9	1
106	Development of an environmental contextual factor item set relevant to global functioning and health in patients with axial Spondyloarthritis. <i>Rheumatology</i> , <b>2021</b> ,	3.9	2
105	Ixekizumab improves spinal pain, function, fatigue, stiffness, and sleep in radiographic axial Spondyloarthritis: COAST-V/W 52-week results. <i>BMC Rheumatology</i> , <b>2021</b> , 5, 35	2.9	0
104	Similar biologic drug response regardless of radiographic status in axial spondyloarthritis: data from the British Society for Rheumatology Biologics Register in Ankylosing Spondylitis registry. <i>Rheumatology</i> , <b>2021</b> , 60, 5795-5800	3.9	2
103	Receptor activator of nuclear factor kappa- $\beta$ ligand (RANKL) serum levels are associated with progression to seropositive/negative rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , <b>2021</b> , 39, 456-462	2.2	1
102	Changes in ankylosing spondylitis incidence, prevalence and time to diagnosis over two decades. <i>RMD Open</i> , <b>2021</b> , 7,	5.9	1
101	The Relationship Between Physical Examination and Ultrasonography of Large Entheses of the Achilles Tendon and Patellar Tendon Origin. <i>Journal of Rheumatology</i> , <b>2020</b> , 47, 1026-1030	4.1	8

100	EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 700-712	2.4	238
99	Axial Psoriatic Arthritis: A Distinct Clinical Entity in Search of a Definition. <i>Rheumatic Disease Clinics of North America</i> , <b>2020</b> , 46, 327-341	2.4	6
98	Genomewide Association Study of Acute Anterior Uveitis Identifies New Susceptibility Loci <b>2020</b> , 61, 3		20
97	FRI0286 IXEKIZUMAB TREATMENT IMPROVES FATIGUE, SPINAL PAIN, STIFFNESS, AND SLEEP IN PATIENTS WITH NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 731-732	2.4	1
96	Biologics and biosimilars in axial spondyloarthritis: Lots of kids on the block!. <i>Indian Journal of Rheumatology</i> , <b>2020</b> , 15, 64	0.5	2
95	Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial. <i>Lancet, The</i> , <b>2020</b> , 395, 53-64	4.0	74
94	Systematic literature review of non-topical treatments for early, untreated (systemic therapy naïve) psoriatic disease: a GRAPPA initiative. <i>Rheumatology Advances in Practice</i> , <b>2020</b> , 4, rkaa032	1.1	1
93	BSR Spondyloarthritis Course, 27 February 2020. Spondyloarthritis: pathogenesis, diagnosis and management. <i>Rheumatology Advances in Practice</i> , <b>2020</b> , 4, rkaa043	1.1	
92	5-year efficacy and safety of secukinumab in patients with ankylosing spondylitis: end-of-study results from the phase 3 MEASURE 2 trial. <i>Lancet Rheumatology, The</i> , <b>2020</b> , 2, e339-e346	14.2	10
91	Non-radiographic versus radiographic axSpA: what's in a name?. <i>Rheumatology</i> , <b>2020</b> , 59, iv18-iv24	3.9	9
90	Axial spondyloarthritis: coming of age. <i>Rheumatology</i> , <b>2020</b> , 59, iv1-iv5	3.9	1
89	Impact of Ixekizumab on Work Productivity in Patients with Ankylosing Spondylitis: Results from the COAST-V and COAST-W Trials at 52 Weeks. <i>Rheumatology and Therapy</i> , <b>2020</b> , 7, 759-774	4.4	3
88	Assessment of SpondyloArthritis International Society (ASAS) Consensus on Spanish Nomenclature for Spondyloarthritis. <i>Reumatología Clínica</i> , <b>2020</b> , 16, 333-338	0.9	3
87	Axial spondyloarthritis: time to stop the split 10 years on. <i>Nature Reviews Rheumatology</i> , <b>2020</b> , 16, 5-6	8.1	1
86	Development of ASAS quality standards to improve the quality of health and care services for patients with axial spondyloarthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 193-201	2.4	24
85	041 It's not only about treating inflammation: clinical psychology intervention for rheumatology patients remains an unmet need in daily practice. <i>Rheumatology</i> , <b>2019</b> , 58,	3.9	1
84	MRI lesions in the sacroiliac joints of patients with spondyloarthritis: an update of definitions and validation by the ASAS MRI working group. <i>Annals of the Rheumatic Diseases</i> , <b>2019</b> , 78, 1550-1558	2.4	81
83	Evidence that tissue resident human enthesis $\gamma$ -cells can produce IL-17A independently of IL-23R transcript expression. <i>Annals of the Rheumatic Diseases</i> , <b>2019</b> , 78, 1559-1565	2.4	69

82	Ixekizumab and complete resolution of enthesitis and dactylitis: integrated analysis of two phase 3 randomized trials in psoriatic arthritis. <i>Arthritis Research and Therapy</i> , <b>2019</b> , 21, 38	5.7	23
81	A comparison of apremilast monotherapy and combination therapy for psoriatic arthritis in a real-life setting: Data from the Leeds Combined Psoriatic Service. <i>Journal of the American Academy of Dermatology</i> , <b>2019</b> , 80, 1796-1798	4.5	2
80	Identification of myeloid cells in the human enthesis as the main source of local IL-23 production. <i>Annals of the Rheumatic Diseases</i> , <b>2019</b> , 78, 929-933	2.4	47
79	Association of Diverticulitis with Prolonged Spondyloarthritis: An Analysis of the ASAS-COMOSPA International Cohort. <i>Journal of Clinical Medicine</i> , <b>2019</b> , 8,	5.1	2
78	Comment on: Emergence of severe spondyloarthropathy-related enthesal pathology following successful vedolizumab therapy for inflammatory bowel disease: reply. <i>Rheumatology</i> , <b>2019</b> , 58, 1115-1119	3.9	11
77	Translating Improvements with Ixekizumab in Clinical Trial Outcomes into Clinical Practice: ASAS40, Pain, Fatigue, and Sleep in Ankylosing Spondylitis. <i>Rheumatology and Therapy</i> , <b>2019</b> , 6, 435-450	4.4	9
76	Emergence of severe spondyloarthropathy-related enthesal pathology following successful vedolizumab therapy for inflammatory bowel disease. <i>Rheumatology</i> , <b>2019</b> , 58, 963-968	3.9	28
75	The advent of IL-17A blockade in ankylosing spondylitis: secukinumab, ixekizumab and beyond. <i>Expert Review of Clinical Immunology</i> , <b>2019</b> , 15, 123-134	5.1	36
74	Increased Risk of Hypertension Associated with Spondyloarthritis Disease Duration: Results from the ASAS-COMOSPA Study. <i>Journal of Rheumatology</i> , <b>2019</b> , 46, 701-709	4.1	10
73	Three-dimensional nail imaging by optical coherence tomography: a novel biomarker of response to therapy for nail disease in psoriasis and psoriatic arthritis. <i>Clinical and Experimental Dermatology</i> , <b>2019</b> , 44, 462-465	1.8	10
72	Ixekizumab improves patient-reported outcomes in patients with active psoriatic arthritis and inadequate response to tumour necrosis factor inhibitors: SPIRIT-P2 results to 52 weeks. <i>Clinical and Experimental Rheumatology</i> , <b>2019</b> , 37, 566-574	2.2	5
71	New advances in the understanding and treatment of axial spondyloarthritis: from chance to choice. <i>Therapeutic Advances in Chronic Disease</i> , <b>2018</b> , 9, 77-87	4.9	30
70	MRI of psoriatic nail disease pre- and post-TNF inhibitor therapy shows persistent subclinical inflammation after 6 months despite good clinical response. <i>RMD Open</i> , <b>2018</b> , 4, e000599	5.9	6
69	Acute Unilateral Sacroiliitis Mimicking Infection on Magnetic Resonance Imaging with Response to Nonsteroidal Antiinflammatory Drugs: A Distinct Presentation of Spondyloarthritis?. <i>Journal of Rheumatology</i> , <b>2018</b> , 45, 1708-1710	4.1	1
68	176 Secukinumab provides sustained reduction in fatigue in patients with ankylosing spondylitis through three years: long-term results of two randomised double-blind placebo-controlled phase III studies. <i>Rheumatology</i> , <b>2018</b> , 57,	3.9	1
67	Measurement properties of the ASAS Health Index: results of a global study in patients with axial and peripheral spondyloarthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2018</b> , 77, 1311-1317	2.4	47
66	Cost Effectiveness of Secukinumab for the Treatment of Active Ankylosing Spondylitis in the UK. <i>Pharmacoeconomics</i> , <b>2018</b> , 36, 1015-1027	4.4	10
65	Short-term Repeat Magnetic Resonance Imaging Scans in Suspected Early Axial Spondyloarthritis Are Clinically Relevant Only in HLA-B27-positive Male Subjects. <i>Journal of Rheumatology</i> , <b>2018</b> , 45, 202-205	4.1	12

64	Cardiovascular risk factors in patients with spondyloarthritis from Northern European and Mediterranean countries: An ancillary study of the ASAS-COMOSPA project. <i>Joint Bone Spine</i> , <b>2018</b> , 85, 447-453	2.9	15
63	Comment on: Tumour necrosis factor inhibitor survival and predictors of response in axial spondyloarthritis-findings from a United Kingdom cohort. <i>Rheumatology Advances in Practice</i> , <b>2018</b> , 2, rky036	1.1	2
62	The Early Phases of Ankylosing Spondylitis: Emerging Insights From Clinical and Basic Science. <i>Frontiers in Immunology</i> , <b>2018</b> , 9, 2668	8.4	51
61	The role of secukinumab in the treatment of psoriatic arthritis and ankylosing spondylitis. <i>Therapeutic Advances in Musculoskeletal Disease</i> , <b>2018</b> , 10, 169-180	3.8	14
60	Efficacy and safety of continuing versus withdrawing adalimumab therapy in maintaining remission in patients with non-radiographic axial spondyloarthritis (ABILITY-3): a multicentre, randomised, double-blind study. <i>Lancet, The</i> , <b>2018</b> , 392, 134-144	4.0	42
59	Serum IL-7 as diagnostic biomarker for rheumatoid arthritis, validation with EULAR 2010 classification criteria. <i>Clinical and Experimental Rheumatology</i> , <b>2018</b> , 36, 115-120	2.2	11
58	Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 Study. <i>Annals of the Rheumatic Diseases</i> , <b>2017</b> , 76, 571-592	2.4	96
57	Secukinumab and Sustained Improvement in Signs and Symptoms of Patients With Active Ankylosing Spondylitis Through Two Years: Results From a Phase III Study. <i>Arthritis Care and Research</i> , <b>2017</b> , 69, 1020-1029	4.7	67
56	2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2017</b> , 76, 978-991	2.4	801
55	Brief Report: Group 3 Innate Lymphoid Cells in Human Enthesis. <i>Arthritis and Rheumatology</i> , <b>2017</b> , 69, 1816-1822	9.5	96
54	Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial. <i>Lancet, The</i> , <b>2017</b> , 389, 2317-2327	4.0	246
53	The Use of Magnetic Resonance Imaging in Axial Spondyloarthritis: Time to Bridge the Gap Between Radiologists and Rheumatologists. <i>Journal of Rheumatology</i> , <b>2017</b> , 44, 780-785	4.1	15
52	The GOLMePsA study protocol: an investigator-initiated, double-blind, parallel-group, randomised, controlled trial of GOLimumab and methotrexate versus methotrexate in early diagnosed psoriatic arthritis using clinical and whole body MRI outcomes. <i>BMC Musculoskeletal Disorders</i> , <b>2017</b> , 18, 303	2.8	8
51	BSR and BHPR guideline for the treatment of axial spondyloarthritis (including ankylosing spondylitis) with biologics. <i>Rheumatology</i> , <b>2017</b> , 56, 313-316	3.9	25
50	Secukinumab provides sustained improvements in the signs and symptoms of active ankylosing spondylitis with high retention rate: 3-year results from the phase III trial, MEASURE 2. <i>RMD Open</i> , <b>2017</b> , 3, e000592	5.9	49
49	Vascularity of nail bed by ultrasound to discriminate psoriasis, psoriatic arthritis and healthy controls. <i>Clinical and Experimental Rheumatology</i> , <b>2017</b> , 35, 872	2.2	12
48	A Phase III, Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis: Results of the PALACE 2 Trial. <i>Journal of Rheumatology</i> , <b>2016</b> , 43, 1724-34	4.1	125
47	AB0700 Baseline Clinical Characteristics of The Leeds Sparro Early Psoriatic Arthritis Cohort: High Disease and Radiographic Involvement Are Seen Early Even in The Presence of Preserved Quality of Life. <i>Annals of the Rheumatic Diseases</i> , <b>2016</b> , 75, 1144.1-1144	2.4	1

46	A2.16 Association of 20 interferon related gene expression with response to infliximab treatment in ankylosing spondylitis: Pilot data. <i>Annals of the Rheumatic Diseases</i> , <b>2016</b> , 75, A21.2-A22	2.4	
45	Measuring impairments of functioning and health in patients with axial spondyloarthritis by using the ASAS Health Index and the Environmental Item Set: translation and cross-cultural adaptation into 15 languages. <i>RMD Open</i> , <b>2016</b> , 2, e000311	5.9	21
44	Defining active sacroiliitis on MRI for classification of axial spondyloarthritis: update by the ASAS MRI working group. <i>Annals of the Rheumatic Diseases</i> , <b>2016</b> , 75, 1958-1963	2.4	259
43	Association of Toll-like receptor 4 (TLR4) with chronic plaque type psoriasis and psoriatic arthritis. <i>Archives of Dermatological Research</i> , <b>2016</b> , 308, 201-5	3.3	29
42	Predictive validity of the ASAS classification criteria for axial and peripheral spondyloarthritis after follow-up in the ASAS cohort: a final analysis. <i>Annals of the Rheumatic Diseases</i> , <b>2016</b> , 75, 1034-42	2.4	44
41	European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. <i>Annals of the Rheumatic Diseases</i> , <b>2016</b> , 75, 499-510	2.4	611
40	Prevalence of comorbidities and evaluation of their screening in spondyloarthritis: results of the international cross-sectional ASAS-COMOSPA study. <i>Annals of the Rheumatic Diseases</i> , <b>2016</b> , 75, 1016-23	2.4	139
39	Tumour necrosis factor- $\alpha$ inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis: a systematic review and economic evaluation. <i>Health Technology Assessment</i> , <b>2016</b> , 20, 1-334, v-vi	4.4	49
38	Evidence of response to IL-6 inhibition in some cases of refractory spondyloarthritis-associated peripheral synovitis. <i>Annals of the Rheumatic Diseases</i> , <b>2016</b> , 75, 1418-20	2.4	8
37	SAT0396 Secukinumab Provides Sustained Improvements in The Signs and Symptoms of Active Ankylosing Spondylitis: 2-Year Results From A Phase 3 Trial with Subcutaneous Loading and Maintenance Dosing (Measure 2). <i>Annals of the Rheumatic Diseases</i> , <b>2016</b> , 75, 812.2-813	2.4	1
36	Poor awareness of inflammatory back pain and axial spondyloarthritis among secondary care specialists. <i>Clinical Rheumatology</i> , <b>2016</b> , 35, 2627-8	3.9	9
35	Observed Incidence of Uveitis Following Certolizumab Pegol Treatment in Patients With Axial Spondyloarthritis. <i>Arthritis Care and Research</i> , <b>2016</b> , 68, 838-44	4.7	57
34	EULAR recommendations for the use of imaging in the diagnosis and management of spondyloarthritis in clinical practice. <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 1327-39	2.4	284
33	Dense genotyping of immune-related susceptibility loci reveals new insights into the genetics of psoriatic arthritis. <i>Nature Communications</i> , <b>2015</b> , 6, 6046	17.4	103
32	Development of a health index in patients with ankylosing spondylitis (ASAS HI): final result of a global initiative based on the ICF guided by ASAS. <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 830-5	2.4	96
31	Screening psoriatic arthritis tools: analysis of the Early Arthritis for Psoriatic Patients questionnaire. <i>Rheumatology</i> , <b>2015</b> , 54, 200-2	3.9	7
30	Association study of genes related to bone formation and resorption and the extent of radiographic change in ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 1387-93	2.4	50
29	OP0128 PTPN22 is Associated with Susceptibility to Psoriatic Arthritis but not Psoriasis: Evidence for a Further PSA-Specific Risk Locus. <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 116.3-117	2.4	0

28	PTPN22 is associated with susceptibility to psoriatic arthritis but not psoriasis: evidence for a further PsA-specific risk locus. <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 1882-5	2.4	49
27	FRI0152 Decreased Employment, Work Productivity, and Presenteeism in Patients with Ankylosing Spondylitis is Associated with Increased Disease Activity as Measured by Basdai. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 437.2-437	2.4	
26	SAT0355 Observed Incidence Rates of Uveitis following Certolizumab Pegol Treatment in Patients with Axial Spondyloarthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 721.3-722	2.4	
25	Magnetic resonance imaging assessment of axial psoriatic arthritis: extent of disease relates to HLA-B27. <i>Arthritis and Rheumatism</i> , <b>2013</b> , 65, 2274-8		36
24	The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project). <i>Annals of the Rheumatic Diseases</i> , <b>2013</b> , 72, 986-91	2.4	192
23	SAT0313 The link between enthesitis and arthritis in psoriatic arthritis: A switch to a vascular phenotype at insertions may play a role in arthritis development. <i>Annals of the Rheumatic Diseases</i> , <b>2013</b> , 71, 578.1-578	2.4	1
22	European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. <i>Annals of the Rheumatic Diseases</i> , <b>2012</b> , 71, 4-12	2.4	355
21	Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility. <i>Nature Genetics</i> , <b>2011</b> , 43, 761-7	36.3	646
20	Magnetic resonance imaging in spondyloarthritis. <i>Current Opinion in Rheumatology</i> , <b>2010</b> , 22, 381-7	5.3	15
19	Defining active sacroiliitis on magnetic resonance imaging (MRI) for classification of axial spondyloarthritis: a consensual approach by the ASAS/OMERACT MRI group. <i>Annals of the Rheumatic Diseases</i> , <b>2009</b> , 68, 1520-7	2.4	538
18	Magnetic resonance imaging in the assessment of metacarpophalangeal joint disease in early psoriatic and rheumatoid arthritis. <i>Scandinavian Journal of Rheumatology</i> , <b>2009</b> , 38, 79-83	1.9	56
17	Baseline and 1-year magnetic resonance imaging of the sacroiliac joint and lumbar spine in very early inflammatory back pain. Relationship between symptoms, HLA-B27 and disease extent and persistence. <i>Annals of the Rheumatic Diseases</i> , <b>2009</b> , 68, 1721-7	2.4	98
16	Evaluation of the diagnostic utility of spinal magnetic resonance imaging in axial spondylarthritis. <i>Arthritis and Rheumatism</i> , <b>2009</b> , 60, 1331-41		98
15	Severity of baseline magnetic resonance imaging-evident sacroiliitis and HLA-B27 status in early inflammatory back pain predict radiographically evident ankylosing spondylitis at eight years. <i>Arthritis and Rheumatism</i> , <b>2008</b> , 58, 3413-8		258
14	A randomized controlled trial of early intervention with intraarticular corticosteroids followed by sulfasalazine versus conservative treatment in early oligoarthritis. <i>Arthritis and Rheumatism</i> , <b>2007</b> , 57, 154-60		25
13	Evidence for a different anatomic basis for joint disease localization in polymyalgia rheumatica in comparison with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , <b>2007</b> , 56, 3496-501		39
12	Is minocycline therapy in acne associated with antineutrophil cytoplasmic antibody positivity? A cross-sectional study. <i>British Journal of Dermatology</i> , <b>2007</b> , 156, 1005-9	4	24
11	Efficacy of infliximab on MRI-determined bone oedema in psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2007</b> , 66, 778-81	2.4	43



10	Early oligoarthritis. <i>Rheumatic Disease Clinics of North America</i> , <b>2005</b> , 31, 627-39	2.4	3
9	Infliximab in combination with methotrexate in active ankylosing spondylitis: a clinical and imaging study. <i>Annals of the Rheumatic Diseases</i> , <b>2005</b> , 64, 1568-75	2.4	122
8	Should oligoarthritis be reclassified? Ultrasound reveals a high prevalence of subclinical disease. <i>Annals of the Rheumatic Diseases</i> , <b>2004</b> , 63, 382-5	2.4	240
7	Efficacy of etanercept for treatment of Crohn's related spondyloarthritis but not colitis. <i>Annals of the Rheumatic Diseases</i> , <b>2003</b> , 62, 74-6	2.4	75
6	The role of biomechanical factors and HLA-B27 in magnetic resonance imaging-determined bone changes in plantar fascia enthesopathy. <i>Arthritis and Rheumatism</i> , <b>2002</b> , 46, 489-93		145
5	Michelangelo and Medicine. <i>Journal of the Royal Society of Medicine</i> , <b>2002</b> , 95, 514-515	2.3	9
4	The concept of disease modification in spondyloarthropathy. <i>Journal of Rheumatology</i> , <b>2002</b> , 29, 1583-5	4.1	18
3	Etanercept treatment in resistant spondyloarthropathy: imaging, duration of effect and efficacy on reintroduction. <i>Clinical and Experimental Rheumatology</i> , <b>2002</b> , 20, S175-7	2.2	5
2	Efficacy of etanercept in the treatment of the enthesal pathology in resistant spondylarthropathy: a clinical and magnetic resonance imaging study. <i>Arthritis and Rheumatism</i> , <b>2001</b> , 44, 2112-7		345
1	Minocycline induced autoimmune disease in rheumatoid arthritis: a missed diagnosis?. <i>Journal of Rheumatology</i> , <b>2001</b> , 28, 377-8	4.1	6